BG64563B1 - Пептиди, метод за получаване и използването им - Google Patents

Пептиди, метод за получаване и използването им Download PDF

Info

Publication number
BG64563B1
BG64563B1 BG102479A BG10247998A BG64563B1 BG 64563 B1 BG64563 B1 BG 64563B1 BG 102479 A BG102479 A BG 102479A BG 10247998 A BG10247998 A BG 10247998A BG 64563 B1 BG64563 B1 BG 64563B1
Authority
BG
Bulgaria
Prior art keywords
nhc
nhch
residue
pro
och
Prior art date
Application number
BG102479A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102479A (en
Inventor
Wilhelm Amberg
Teresa Barlozzari
Harald Bernard
Ernst Buschmann
Andreas Haupt
Hans-Guenther Hege
Bernd Janssen
Andreas Kling
Helmut Lietz
Kurt Ritter
Martina Ullrich
Juergen Weymann
Thomas Zierke
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG102479A publication Critical patent/BG102479A/xx
Publication of BG64563B1 publication Critical patent/BG64563B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG102479A 1995-12-15 1998-05-22 Пептиди, метод за получаване и използването им BG64563B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57342295A 1995-12-15 1995-12-15

Publications (2)

Publication Number Publication Date
BG102479A BG102479A (en) 1999-06-30
BG64563B1 true BG64563B1 (bg) 2005-07-29

Family

ID=24291935

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102479A BG64563B1 (bg) 1995-12-15 1998-05-22 Пептиди, метод за получаване и използването им

Country Status (30)

Country Link
EP (2) EP1593686B1 (pl)
JP (1) JP3939354B2 (pl)
KR (1) KR100463739B1 (pl)
CN (1) CN1127514C (pl)
AR (1) AR004382A1 (pl)
AT (2) ATE471944T1 (pl)
AU (2) AU731458B2 (pl)
BG (1) BG64563B1 (pl)
BR (1) BR9611987A (pl)
CA (1) CA2237721C (pl)
CO (1) CO4750840A1 (pl)
CZ (1) CZ296908B6 (pl)
DE (2) DE69633457T2 (pl)
DK (1) DK0866800T3 (pl)
ES (1) ES2229287T3 (pl)
HR (1) HRP960585A2 (pl)
HU (1) HU228275B1 (pl)
IL (2) IL124342A (pl)
MX (1) MX9803953A (pl)
MY (1) MY114327A (pl)
NO (1) NO319273B1 (pl)
NZ (1) NZ324691A (pl)
PL (1) PL186721B1 (pl)
PT (1) PT866800E (pl)
RU (1) RU2182911C2 (pl)
SK (1) SK285286B6 (pl)
TR (1) TR199801102T2 (pl)
TW (1) TW474946B (pl)
WO (1) WO1997022621A2 (pl)
ZA (1) ZA9610510B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879276A (en) * 1983-12-19 1989-11-07 Uniroyal Chemical Ltd./Uniroyal Chemical Ltee Method for reducing serum uric acid levels
WO1993023424A1 (en) * 1992-05-20 1993-11-25 Basf Aktiengesellschaft Derivatives of dolastatin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE69329425T2 (de) * 1992-12-16 2001-01-18 Basf Ag Dolastatin analog
DE4415998A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
DE4415997A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neuer peptidischer Wirkstoff und dessen Herstellung
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879276A (en) * 1983-12-19 1989-11-07 Uniroyal Chemical Ltd./Uniroyal Chemical Ltee Method for reducing serum uric acid levels
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
WO1993023424A1 (en) * 1992-05-20 1993-11-25 Basf Aktiengesellschaft Derivatives of dolastatin

Also Published As

Publication number Publication date
SK76798A3 (en) 1999-02-11
AR004382A1 (es) 1998-11-04
WO1997022621A2 (en) 1997-06-26
TW474946B (en) 2002-02-01
ATE277076T1 (de) 2004-10-15
DE69638206D1 (de) 2010-08-05
IL124342A (en) 2005-06-19
CA2237721C (en) 2008-01-29
NO319273B1 (no) 2005-07-11
KR20000064400A (ko) 2000-11-06
CN1204342A (zh) 1999-01-06
NO982711D0 (no) 1998-06-12
AU731458B2 (en) 2001-03-29
EP0866800A2 (en) 1998-09-30
NZ324691A (en) 1999-11-29
PT866800E (pt) 2005-01-31
KR100463739B1 (ko) 2005-02-28
ZA9610510B (en) 1998-06-15
IL124342A0 (en) 1998-12-06
CZ184698A3 (cs) 1998-09-16
SK285286B6 (sk) 2006-10-05
BG102479A (en) 1999-06-30
CZ296908B6 (cs) 2006-07-12
AU1192597A (en) 1997-07-14
MX9803953A (es) 1998-09-30
EP0866800B1 (en) 2004-09-22
HU228275B1 (en) 2013-02-28
NO982711L (no) 1998-06-12
MY114327A (en) 2002-09-30
JP2000502092A (ja) 2000-02-22
DK0866800T3 (da) 2005-01-17
ATE471944T1 (de) 2010-07-15
ES2229287T3 (es) 2005-04-16
TR199801102T2 (xx) 1998-12-21
PL186721B1 (pl) 2004-02-27
PL327175A1 (en) 1998-11-23
HUP0000172A3 (en) 2000-09-28
WO1997022621A3 (en) 1998-02-26
JP3939354B2 (ja) 2007-07-04
DE69633457T2 (de) 2005-09-22
DE69633457D1 (de) 2004-10-28
EP1593686B1 (en) 2010-06-23
AU2004220772B2 (en) 2008-06-12
BR9611987A (pt) 1999-02-17
CN1127514C (zh) 2003-11-12
CO4750840A1 (es) 1999-03-31
HRP960585A2 (en) 1998-02-28
AU2004220772A1 (en) 2004-11-11
RU2182911C2 (ru) 2002-05-27
CA2237721A1 (en) 1997-06-26
HUP0000172A2 (en) 2000-07-28
IL166853A (en) 2013-03-24
EP1593686A1 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
AU679479B2 (en) Dolostatin analog
AU725164B2 (en) Novel dolastatin derivatives, their preparation and use
WO1993023424A1 (en) Derivatives of dolastatin
IL166853A (en) Antineoplastic peptides, their preparation and various uses thereof
US8440626B2 (en) Antineoplastic peptides
AU775090B2 (en) Antineoplastic peptides
SK165497A3 (en) Peptides, preparation method thereof and pharmaceutical composition containing the same